Milestone Pharmaceuticals (MIST) Q3 2026 earnings review
Milestone's heart spray sales grow, and cost cuts extend cash
Milestone Pharmaceuticals, the maker of the Cardamyst heart-rhythm nasal spray, is cutting costs to make its cash last while its first drug rollout builds. Product sales rose 73% from last quarter to $1.0 million, and commercial insurers now cover about two-thirds of insured Americans. To fund the business through late 2028 clinical trial results, chief executive Joseph Oliveto unveiled a 30% operating expense cut, trimmed the sales force to 45 representatives, and deferred cash interest on its debt.
| Cardamyst net product sales | $1.0M +73% from last quarter |
|---|---|
| Prescriptions written since launch | ~3,400 1,500 filled through Q2 |
| Commercial insurance coverage | ~67% 25% at the end of Q2 |
| Cash runway outlook | Late 2028 extended from second half of 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because the company defused its biggest near-term risk: running out of cash next year before its second-half 2028 AFib-RVR trial readout. Extending the cash outlook into late 2028 removes the immediate threat of a dilutive share sale, while wider insurance coverage is starting to lift net revenue per prescription toward $500 by our math. One caution: shrinking the sales force by a quarter just eight months into the launch and letting the finance and medical chiefs go could slow doctor adoption.
The question now is whether a smaller 45-person sales team and reduced marketing budget can keep prescriptions climbing while new insurance coverage converts free trial doses into paid sales. If newly covered insurers pay up and existing doctors write repeat prescriptions, revenue will outpace script growth and validate the leaner model; if doctor outreach stalls under the smaller team, sales will stay too small to cover even the reduced $20 million quarterly expense run rate. Fourth-quarter product sales and net revenue per filled prescription will tell.
🐂 Bull Case
Cost Cuts and Debt Deal Push Cash Past Trial Data
Milestone Pharmaceuticals develops heart drugs and spent the first half of the year burning cash faster than its launch could bring it in. Its previous plan only funded the business into the second half of 2027, leaving a gap before its next major clinical trial results in late 2028.
The company closed that gap through two actions. It unveiled a restructuring to cut operating expenses by about 30% by the first quarter of 2027. It also amended its loan with lender RTW Investments, which "extends the payment-in-kind interest period on its convertible notes from March 31, 2027 to March 2029" so the drugmaker pays interest in debt rather than cash.
This matters because the company now expects its $145.4 million cash pile to last "into late 2028, more than one year beyond prior guidance". Stretching the money past the second-half 2028 trial readout for AFib-RVR, a rapid irregular heartbeat condition with three to four million US patients, removes the immediate need to sell new shares at low prices.
What to watch: total operating expenses in the first quarter of 2027, when the cuts finish. A drop toward $19.6 million a quarter by our math would confirm the savings are on track to preserve cash through late 2028.
Prescriptions and Payer Coverage Keep Expanding
Cardamyst is Milestone's self-administered nasal spray for sudden episodes of rapid heartbeat known as PSVT. The commercial rollout is in its third quarter, and both patient demand and insurance coverage are rising steadily.
- Net product sales: $963 thousand, up 72.3% from $559 thousand last quarter
- Total prescriptions: about 3,400 written since launch, up by 1,900 from the 1,500 filled through June by our math
- Unique prescribers: about 1,600 doctors since launch, double the 800 reached through June
- Commercial insurance coverage: about two-thirds of covered lives, up from 25% at the end of June
Wider insurance coverage matters because pharmacies reject fewer claims, so doctors face less paperwork and the drugmaker gives away fewer free starter doses. By our math, cumulative prescriptions per doctor ticked up from 1.9 in the second quarter to 2.1 in the third, showing early repeat writing among cardiologists and heart-rhythm specialists.
What to watch: fourth-quarter net product revenue and prescription volume. Faster revenue growth than prescription growth would prove that two-thirds insurance coverage is converting free trial doses into paid sales.
Positives this quarter didn't test
One commercial initiative from last quarter received no standalone performance numbers in the third-quarter release.
- Direct-to-patient digital marketing: management launched targeted online ads gated on insurance coverage last quarter, and while the company will now "concentrate on its most productive targeted marketing", only patient self-request or website traffic numbers on the call would show whether digital ads are driving prescriptions.
🐻 Bear Case
Milestone Cut Its Sales Force Eight Months Into Launch
"The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses," chief executive Joseph Oliveto said. Selling, general and administrative expenses — the cost of the sales force, marketing and corporate overhead — reached $24.2 million this quarter, up from $7.9 million a year ago.
Yet the actions shrink the commercial footprint just eight months after the February launch. In August, the drugmaker cut its field sales team by 25%, from about 60 representatives to 45, to "focus on the strongest-performing representatives and territories". It is now converting those 45 contractors into company employees, cutting headquarters staff, and "discontinuing less productive initiatives" in marketing and patient support.
Pulling back so early tests Oliveto's claim because the sales team had called on only about half of its 10,000 target doctors by mid-year. Fewer representatives and smaller marketing budgets make it harder to reach untouched clinics and remind one-time prescribers to write the drug again.
What to watch: new unique prescribers added in the fourth quarter and first quarter of 2027. A slowdown from the 800 doctors added this quarter would show the smaller 45-person sales team is limiting the rollout's reach.
Discounts and Cost of Goods Weigh on Drug Economics
Cardamyst's long-term commercial target is $500 to $1,000 in net revenue for every prescription filled. Early in the launch, patient assistance programs and free doses for uninsured patients held realized prices well below that range.
- Implied net revenue per script: about $507 in Q3 by our math ($963 thousand divided by 1,900 new scripts), up from $466 in Q2
- Product gross margin: 66.3% in Q3 (cost of sales of $325 thousand), down 28.0 percentage points from 94.3% in Q2 by our math
- Receivables and deferred revenue: $3.93 million and $1.32 million on the balance sheet, or 5.5 times Q3 net product sales
The $507 figure slightly overstates true pricing because the company switched from reporting filled prescriptions in Q2 to prescriptions written in Q3. Meanwhile, cost of product sales jumped tenfold from $32 thousand in Q2 to $325 thousand, and unpaid distributor bills plus deferred revenue sit at more than five times quarterly sales, pointing to heavy rebates and distributor stocking.
What to watch: product gross margin and the gap between written and filled prescriptions in the quarterly filing. If rebates and manufacturing costs keep net value per filled script below $500, revenue will lag prescription growth.
Risks this quarter didn't answer
Five standing clinical, commercial and financial risks received no new figures in the earnings release.
- Medicare coverage: roughly 45% of PSVT patients are on Medicare, where coverage is still not expected until 2027; any 2027 Part D contract announcement will move this.
- Repeat prescribing rate: the release gave cumulative totals rather than how many doctors wrote a second script or how many patients refilled; conference call commentary will test depth.
- Phase 3 AFib-RVR enrollment: management said the ReVeRA-301 trial is on schedule for 2028 data, but did not confirm whether the first patient was enrolled this half.
- Royalty rate step-up: the RTW royalty debt reached $82.8 million, and the annual sales thresholds that would raise the royalty rate from 7% to 9.5% remain undisclosed in the release.
- Manufacturing concentration: Milestone relies on single-source suppliers and noted that "non-essential short-term activities, including certain manufacturing scale-up work, have been deferred".
👓 Other Themes
Cost-Reduction Plan Reshapes Operations and Leadership
To achieve its 30% expense cut by the first quarter of 2027, the drugmaker will take about $2 million in one-time charges for severance and fees to convert its 45 contract sales representatives into employees. As part of the downsizing, finance chief Amit Hasija and medical chief David Bharucha left the executive team; Bharucha stays on as an advisor, while vice president Anthony Krick takes over finance.
💲 Other KPIs
Cash and short-term investments fell by $25.3 million from $170.6 million at the end of June by our math, a wider drop than the $13.6 million decrease in Q2 when warrant exercises brought in cash. Research and development spending fell 12.2% from a year ago to $3.5 million, while net loss widened to $25.8 million.
Combined long-term debt rose from $141.0 million in Q2 to $143.1 million by our math, consisting of $60.2 million in convertible notes and $82.8 million in royalty financing obligations. Non-cash interest accretion on those two liabilities pushed quarterly interest expense to $2.2 million and swung shareholders' equity into a $6.2 million deficit.
Net inventory on the balance sheet grew 41.4% from last quarter to $6.7 million, up from $0.6 million at year-end, as the company builds commercial supply. Separately, the Canadian group booked $2.0 million in one-time license revenue during Q3, matching a $2.0 million license receivable on the balance sheet.
Weighted average shares and pre-funded warrants rose 46.0% from 96.5 million a year ago after equity raises in late 2025 and early 2026, holding loss per share to $0.18 versus $0.12 a year ago. Share issuance paused in Q3, with period-end common shares unchanged from June at 124.5 million.
🔮 Guidance
Raised. Milestone now expects its $145.4 million in cash and short-term investments to fund operations into late 2028, adding more than a year to its prior second-half 2027 plan. The extension relies on cutting operating expenses by 30% and deferring cash interest on its convertible notes until March 2029, stretching funds past the expected second-half 2028 AFib-RVR trial readout.
New. The plan targets an approximate 30% cut in operating expenses once completed in the first quarter of 2027, alongside about $2 million in one-time severance and conversion charges. By our math, a 30% reduction from Q3's $28.0 million operating spend implies a quarterly run rate near $19.6 million starting next spring.
Unchanged. The company stated that its Phase 3 ReVeRA-301 trial in AFib-RVR is on schedule and set an explicit topline readout window in the second half of 2028. That timeline aligns with prior statements of an approximately two-year study starting in the second half of 2026, and the trial remains fully funded under the new cost plan.
❓ Key Questions
How many Q3 prescriptions were filled and paid for?
The release reported 3,400 cumulative prescriptions written since launch, whereas prior quarters tracked prescriptions filled. Investors need the Q3 filled count and the split between free patient-assistance doses and paid scripts to see whether net price is genuinely rising.
Why did cost of product sales jump tenfold in Q3?
Cost of product sales rose from $32 thousand in Q2 to $325 thousand in Q3, knocking product gross margin down from 94.3% to 66.3% by our math. Management did not say whether fixed manufacturing overhead, scrap or royalty expenses caused the jump.
What triggered the $2.0 million license revenue in Q3?
Milestone booked $2.0 million in license and other revenue alongside a $2.0 million license receivable on the balance sheet, without naming the partner or milestone in the release text. Clarifying whether this came from China partner Everest Medicines or Europe matters for cash flow.
Has the first patient enrolled in the ReVeRA-301 trial?
Prior quarters set a target to enroll the first AFib-RVR Phase 3 patient in the second half of 2026. The Q3 release said the trial is on schedule for second-half 2028 data but did not state whether patient dosing has begun.
Where stands the European regulatory review for PSVT?
In the first and second quarters, management highlighted an expected European Medicines Agency decision on its marketing application in the first half of 2027. The Q3 release dropped the European review from its operational highlights without giving a status update.